Maintenance therapy in lymphoma

Clinical Lymphoma and Myeloma

Volumn 7, Issue 8, 2007, Pages 507-513

  Mihelic, Ronald ^a   Kaufman, Jonathan ^a   Lonial, Sagar ^a   Flowers, Christopher ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

CHOP; CVP; Cyclophosphamide; Diffuse large B cell lymphoma; Interferon; Prednisone; Rituximab; Vincristine

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOXANTRONE; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL XL; RITUXIMAB; VINCRISTINE;

B CELL LYMPHOMA; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 35848956349     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.034     Document Type: Review

References (48)

1. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncal 1993; 20:75-88.
2. Lamanna N, Weiss M. Treatment options for newly diagnosed patients with adult acute lymphoblastic leukemia. Curr Hematol Rep 2004; 3:40-46.
3. Sweetenham JW, Santini G, Qian W, et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001; 19:2927-2936.
4. Rohatiner A, Radford J, Deakin D, et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001; 85:29-35.
5. Allen IE, Ross SD, Borden SP, et al. Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma. J Immunother 2001; 24:58-65.
6. Fisher RI, Dana BW, LeBlanc M, et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000; 18:2010-2016.
7. Aviles A, Cleto S, Huerta-Guzman J, et al. Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens. Eur J Haematol 2001; 66:94-99.
8. Aviles A, Talavera A, Diaz NR, et al. Interferon as maintenance therapy in refractory malignant lymphoma. J Hematother 1999; 8:263-267.
9. Giles FJ, Shan J, Advani SH, et al. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study. Leuk Lymphoma 2000; 40:95-103.
10. Hainsworth JD, Litchy S, Burris HA III, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002; 20:4261-4267.
11. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of tituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkins lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23:1088-1095.
12. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416-4423.
13. Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005; 16:1675-1682.
14. Basham T, Merigan TC. Immunoregulation by gamma-interferon? Nature 1982; 299:778.
15. Basham TY, Bourgeade MF, Creasey AA, et al. Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. Proc Natl Acad Sci USA 1982; 79:3265-3269.
16. Heron I, Hokland M, Berg K. Enhanced expression of beta2-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci USA 1978; 75:6215-6219.
17. Joshua DE, MacCallum S, Gibson J. Role of alpha interferon in multiple myeloma. Blood Rev 1997; 11:191-200.
18. D'Cunha J, Ramanujam S, Wagner RJ, et al. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol 1996; 157:4100-4108.
19. Lonial S, Waller EK, Simons JW, et al. Signal transduction and myeloma: new targets, new hope. Cancer Biol Ther 2003; 2:310-319.
20. Raulet DH, Bevan MJ. A differentiation factor required for the expression of cytotoxic T-cell function. Nature 1982; 296:754-757.
21. Sato N, Nariuchi H, Tsuruoka N, et al. Actions of TNF and IFN-gamma on angiogenesis in vitro. J Invest Dermatol 1990; 95(6 suppl):85s-89s.
22. Siegel JP. Effects of interferon-gamma on the activation of human T lymphocytes. Cell Immunol 1988; 111:461-472.
23. Foon KA, Sherwin SA, Abrams PG, et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984; 311:1148-1152.
24. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of Interferon in follicular lymphoma. J Clin Oncol 2005; 23:2215-2223.
25. Arranz R, García-Alfonso P, Sobrino P, et al. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998; 16:1538-1546.
26. Jazirehi AR, Huerta-Yepez S, Cheng G, et al. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65:264-276.
27. Vega MI, Huerta-Yepez S, Jazirehi AR, et al. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 2005; 24:8114-8127.
28. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417-1423.
29. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-1932.
30. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engll Med 2002; 346:235-242.
31. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cefl lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117-4126.
32. Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9:995-1001.
33. Gordan LN, Grow WB, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005; 23:1096-1102.
34. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
35. Hochster HS, Weller E, Gascoyne RD, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 2005; 106:106a (Abstract #349).
36. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III Intergroup trial. Blood 2006; 108:3295-3301.
37. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108:4003-4008.
38. Habermann T, Weller E, Morrison VA, et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood 2004; 104:40a (Abstract #127).
39. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23:705-711.
40. Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology' Network. Ann Oncol 2006; 17:1418-1423.
41. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20:1288-1294.
42. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105:2677-2684.
43. Diaz N, Osmanov EA, Alexeeva YA, et al. Safety and tolerability of the combination of interleukin-2 (rIL-2) and rituximab in patients with refractory/relapsed follicular non Hodgkin lymphoma. Preliminary data from the Pearl study. Blood 2005; 106:276b (Abstract #4783).
44. Hernandez-Ilizaliturri FJ, Jupudy V, Reising S, et al. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leuk Lymphoma 2005; 46:1775-1784.
45. Kimby E. Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor [corrected]. Semin Oncol 2002; 29(2 suppl):7-10.
46. Leonard JP, Zelentz AD, Vose JM, et al. Impact of course of therapy on response rate and duration with the Bexxar" therapeutic regimen (tositumomab and iodine 1131 tositumomab) and with chemotherapy. Blood 2004; 104:41a (Abstract # 132).
47. Press OW, Unger J, Maloney D, et al. An update of a phase II trial of CHOP followed by tositumomab/iodine I-131 tositumomab (Bexxar®) for front-line treatmenr of advanced stage, follicular lymphoma: Southwest Oncology Group Protocol 9911. Blood 2005; 106:107a (Abstract #352).
48. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007; 25:1741-1746.